Haemonetics Hold Rating Persists Despite 6.8% Q3 Surprise, 8.1% Growth Forecast
Haemonetics reported Q3 earnings that beat consensus with an average surprise of +6.8%, prompting one analyst to raise fiscal 2026 estimates by $0.01 to $4.94 per share. The company holds a Zacks #3 Rank with A-rated VGM and B-rated Growth scores forecasting 8.1% year-over-year earnings growth.
1. Q3 Earnings Performance
Haemonetics delivered third-quarter earnings that surpassed analyst expectations, resulting in an average earnings surprise of +6.8%. Key revenue drivers included strength in blood management devices and higher utilization of plasma collection systems.
2. Analyst Estimate Revisions
Following the better-than-expected results, one analyst increased the fiscal 2026 EPS forecast by $0.01 to $4.94. This adjustment reflects confidence in sustained operational momentum and improved margin trends.
3. Zacks Style Score Assessment
Haemonetics carries a Zacks Rank #3 (Hold) but boasts an A-rated VGM Score and a B-rated Growth Score. The Growth Score projects 8.1% year-over-year earnings growth, highlighting solid future prospects despite the neutral rank.